Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tannapfel

Showing results (201-210 of 213) with videos related to

Pageof 22
Sort By:
Zeitschrift Fur Gastroenterologie|August 17, 2016
[HER2 testing in gastric cancer - results of a German expert meeting]F Lordick, S E Al-Batran, R D Hofheinz, et al.
Zentralblatt Fur Chirurgie|May 23, 2007
[Report on the workshop "workflow rectal cancer II" in Burghausen]R Bittner, J Burghardt, E Gross, et al.
Zentralblatt Fur Chirurgie|May 23, 2007
[Quality indicators for diagnostic and therapy of rectal carcinoma]R Bittner, J Burghardt, E Gross, et al.
ESMO Open|August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFIA H S Alig, D P Modest, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupD P Modest, I Ricard, V Heinemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2016
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trialJ Quidde, S Hegewisch-Becker, U Graeven, et al.
Der Pathologe|February 26, 2003
[Histopathological diagnosis of Barrett's mucosa and associated neoplasias. Results of a consensus conference of the Working Group for "Gastroenterological Pathology of the German Society for Pathology" on 22 September 2001]G Faller, R Berndt, F Borchard, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)A Kurreck, M Geissler, U M Martens, et al.
Zentralblatt Fur Chirurgie|August 19, 2009
[Diagnosis of and therapy for gastric cancer--work-flow]R T Grundmann, A H Hölscher, A Bembenek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) - an AIO / ABCSG trialG Folprecht, S Stasik, A Reinacher-Schick, et al.
Pageof 22

Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
Zeitschrift Fur Gastroenterologie|August 17, 2016
[HER2 testing in gastric cancer - results of a German expert meeting]F Lordick, S E Al-Batran, R D Hofheinz, et al.
Zentralblatt Fur Chirurgie|May 23, 2007
[Report on the workshop "workflow rectal cancer II" in Burghausen]R Bittner, J Burghardt, E Gross, et al.
Zentralblatt Fur Chirurgie|May 23, 2007
[Quality indicators for diagnostic and therapy of rectal carcinoma]R Bittner, J Burghardt, E Gross, et al.
ESMO Open|August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFIA H S Alig, D P Modest, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupD P Modest, I Ricard, V Heinemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2016
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trialJ Quidde, S Hegewisch-Becker, U Graeven, et al.
Der Pathologe|February 26, 2003
[Histopathological diagnosis of Barrett's mucosa and associated neoplasias. Results of a consensus conference of the Working Group for "Gastroenterological Pathology of the German Society for Pathology" on 22 September 2001]G Faller, R Berndt, F Borchard, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)A Kurreck, M Geissler, U M Martens, et al.
Zentralblatt Fur Chirurgie|August 19, 2009
[Diagnosis of and therapy for gastric cancer--work-flow]R T Grundmann, A H Hölscher, A Bembenek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) - an AIO / ABCSG trialG Folprecht, S Stasik, A Reinacher-Schick, et al.
Pageof 22